Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial
Janine Makaronidis
Nature Medicine, Published online: 22 May 2026; doi:10.1038/s41591-026-04416-4 At week 68, in patients who experienced poor weight loss following bariatric surgery, semaglutide was associated with 18.0% weight loss compared to 0.4% weight gain in patients receiving placebo.